Compare PPG Industries, Inc. (PPG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? PPG Industries, Inc. trades at $103.96 (market cap $23.44B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: PPG Industries, Inc. is far larger — about 2.3× State Street SPDR S&P Biotech ETF's market cap, and PPG Industries, Inc. pays a 2.81% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PPG | XBI | |
|---|---|---|
Market Cap | $23.44B | $10.11B |
Volume | 2,064,777 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $131.56 | $169.55 |
52-Week Low | $94.34 | $104.99 |
Typical Hold Time | 68 Days | 38 Days |
Enterprise Value | $29.31B | — |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $103.96, down 1.07% today, with mixed technical signals showing bearish momentum but neutral oscillators. The company maintains solid fundamentals with a P/E of 15.13, net income margin of 9.57%, and consistent dividend payments. Recent earnings show volatility with Q2 2026 missing expectations, while analyst consensus remains bullish with a $130 price target representing 25% upside potential.
PPG presents a balanced investment case with strong profitability metrics and analyst support, though near-term headwinds in automotive refinish and European markets create uncertainty. The stock's current valuation appears reasonable relative to historical levels, but investors should monitor Q3 2026 earnings on October 27 for confirmation of growth trajectory amid ongoing margin pressures.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
